First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases

Por Helmer, Eric, Watling, Mark, Jones, Emma, Tytgat, Dominique, Jones, Mark, Allen, Rodger, Payne, Andrew, Koch, Annelize, Healy, Eugene
Publicado no Eur J Clin Pharmacol (2017)

First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis

Por Glatt, Sophie, Helmer, Eric, Haier, Birgit, Strimenopoulou, Foteini, Price, Graham, Vajjah, Pavan, Harari, Olivier A., Lambert, John, Shaw, Stevan
Publicado no Br J Clin Pharmacol (2017)